Moderna (MRNA) Study Finds Lower COVID-19 Risks Versus Comirnaty

What happened

A real-world observational study of 294,499 U.S. veterans aged 65 and older found Moderna’s mNEXSPIKE was associated with 35.9% lower medically attended COVID-19 risk and 47.0% lower COVID-19-associated hospitalization risk than Comirnaty. The study does not establish that the vaccine caused these differences.

Confirmed

Global impact / market context

The results could strengthen mNEXSPIKE’s case with older adults and healthcare decision-makers, potentially supporting use and sales. However, the observational design cannot show the vaccine caused lower risks, so the findings alone do not confirm a commercial advantage or a change in revenue.

Analyst inference

This is comparative real-world evidence for an existing Moderna vaccine, not a new product launch or reported financial result. The study’s older, predominantly male veteran group may not represent broader populations, limiting how confidently investors can translate its findings into expected demand.

Confirmed

What to watch

1. Look for additional comparative evidence in broader populations; results across different groups would help clarify whether the observed risk differences apply beyond older U.S. veterans. Analyst inference
2. Watch for disclosures on mNEXSPIKE uptake or revenue, which would show whether the study’s findings are translating into commercial demand rather than only clinical interest. Analyst inference
3. The study also reported an exploratory estimate for fewer hospitalizations involving major heart-related events; because the result was associative, it does not establish that the vaccine caused the difference. Confirmed

Evidence

• Original source link unavailable